Greywolf Therapeutics’ Post

According to Indus Health Plus’s retrospective analysis data (unpublished), around 2.3% of Indians are intermediate metabolizers of DPYD associated medications like 5-fluorouracil. 5-FU (fluorouracil) is commonly used in breast cancer treatment, especially in advanced stages or as part of combination therapies for adjuvant treatment. However, patients with decreased or non-functioning DPYD alleles may struggle to metabolize this drug effectively. This can lead to severe side effects such as nausea, vomiting, diarrhea, and even life-threatening bone marrow suppression. Genetic testing for DPYD can identify patients at risk, allowing for necessary dose adjustments and therapeutic drug monitoring to ensure safer, more effective treatment. Take action today! If you or someone you know is undergoing breast cancer treatment, consider getting tested. Protect your health and make informed decisions about your care. #HealthcareLeadership #BreastCancerAwareness #IndusHealthPlus #PinkOctober #DPYD #5FU #GeneticTesting

According to Indus Health Plus’s retrospective analysis data (unpublished), around 2.3% of Indians are intermediate metabolizers of DPYD associated medications like 5-fluorouracil. 5-FU (fluorouracil) is commonly used in breast cancer treatment, especially in advanced stages or as part of combination therapies for adjuvant treatment. However, patients with decreased or non-functioning DPYD alleles may struggle to metabolize this drug effectively. This can lead to severe side effects such as nausea, vomiting, diarrhea, and even life-threatening bone marrow suppression. Genetic testing for DPYD can identify patients at risk, allowing for necessary dose adjustments and therapeutic drug monitoring to ensure safer, more effective treatment. Take action today! If you or someone you know is undergoing breast cancer treatment, consider getting tested. Protect your health and make informed decisions about your care. #HealthcareLeadership #BreastCancerAwareness #IndusHealthPlus #PinkOctober #DPYD #5FU #GeneticTesting #KnowBetterLiveBetter

RM is a 55 year-old female with metastatic endometrioid adenocarcinoma of the endometrium who was initially treated with carboplatin and paclitaxel followed by a phase I clinical trial with a novel PI3K inhibitor. She developed a new lower quadrant mass that was biopsied and confirmed to be recurrent disease. The sample was sent for NGS testing and found to be MSI-High. Which of the following treatment options is the most appropriate for RM at this time? A. Nivolumab B. Nivolumab and ipilimumab C. Pembrolizumab D. Atezolizumab

https://lnkd.in/gzigwYJH                                                  Article title: The Biological Effects of Interleukin-6 and Their Clinical Applications in Autoimmune Diseases and Cancers   Author(s): Deng-Ho Yang Journal: Rheumatica Acta: Open Access   Journal ISSN: 2640-799X Abstract: Interleukin-6 (IL-6) is one of the pro-inflammatory cytokines involved in pathogenesis of various autoimmune and chronic inflammatory diseases. IL-6 through binding to its cellular receptor can transduce both classical- and trans-signaling pathways. Overproduction of circulating IL-6 can be detected in patients with different autoimmune diseases. Tocilizumab, a humanized monoclonal antibody against IL-6 receptor, can block IL-6-mediated signaling and has been approved for the treatment of rheumatoid arthritis and Castleman’s disease. #IL6 #AutoimmuneDisease #Cancer #Inflammation #ArthriticDisease #ChronicInflammatoryArthritis #ClinicalRheumatology #Peertechz #PeertechzPublications #ExperimentalRheumatology #Plaquenil #PolymyalgiaRheumaticaTreatment #Polymyositis #RheumaticDiseases #RheumatoidArthritisDiagnosis #RheumatologistsCommunications #RheumatologyAndInternalMedicine #RheumatologyCaseReports #RheumatologyPractice #RheumatologyResearch #SystemicSclerosis

This amazing development could see the cure of autoimmune diseases in 5- 10 years. Read this article about how #car-t therapies cured severe lupus in several patients. Waiting for larger trials. CAR T was first approved by the U.S. Food and Drug Administration in 2017 as a major breakthrough for certain blood cancers. The name refers to chimeric antigen receptors, which recognize antigens from tumor cells to target them for destruction. The therapy is currently ex vivo, meaning that some of a patient’s own T cells are removed, modified in a lab with the CAR that will precisely hunt down their cancer, and reinfused back into the body. The engineered T cells act like a living drug, on guard 24/7 to seek out and destroy the patient’s pathogenic cells, while leaving other cells intact. https://lnkd.in/d-mVMZaF

SmartVascular Dx™ (SVDx) accurately diagnoses clinically significant vascular inflammation associated with clinical conditions such as infections, autoimmune diseases, cancer, COVID-19, and metabolic abnormalities, all of which have an increased risk of heart attack and stroke. SVDx is a groundbreaking serum blood test that combines seven protein biomarkers with 4 clinical factors. Acting as a “check engine light,” it is designed to uncover chronic subclinical vascular inflammation that conventional tests may overlook. This proactive approach allows for timely intervention and early prevention strategies. Learn more at: https://lnkd.in/gy4269FQ

🔍 Rethinking Immuno-Oncology Failures as New Hope for Autoimmune Diseases 🔍 Not every immuno-oncology target has been a home run. But what if some of the "misses" in oncology—targets like CD40L and OX40—could offer breakthroughs in a different setting? Enter inverse-I/O: the strategy of targeting immune pathways for suppression rather than activation, with promising Phase 3 studies already underway for CD40L and OX40L in autoimmune diseases. The latest post explores: 👉 The potential of inverse-I/O targets like CD40L and OX40L to address autoimmune needs 👉 How companies like Sanofi and Amgen are leading the way with advanced Phase 3 programs 👉 Why “flipping the script” on I/O targets could reveal untapped therapeutic opportunities Dive into the details on how inverse-I/O could reshape immune-targeted therapies and open doors for novel treatments in autoimmune and inflammatory diseases. L1nk in the comments!

Register now for our upcoming webinar titled, "From the Lab to the Bench: Scaling up Regulatory T Cell Therapy." Register here: https://lnkd.in/ecATwDXD Date: Thursday, September 12th, 2024 Time: 11:00 EST Regulatory T cells (Tregs) play a critical role in maintaining immune balance and preventing autoimmune diseases. Join us to explore the potential of Treg expansion as a promising therapeutic approach. Our webinar will talk about a novel technology that provides an optimized activation signal for Treg expansion, ensuring a high-fold increase in suppressive Tregs with a stable FOXP3 phenotype and more! 1. Learn how a relevant number of regulatory T cells is achieved with 800-fold expansion after two stimulations 2. Hear how Tregs can be activated and expanded in a closed, automated system 3. How CAR-engineered Tregs can induce immune tolerance Register here: https://lnkd.in/etXqDKXZ

For those of you at #ESMO24 - we, #jazzpharma, are presenting updated Phase 2 trial data showing the potential of our investigational dual HER2-targeted bispecific antibody in treating patients with HER2-expressing advanced or metastatic gastroesophageal adenocarcinoma (mGEA).

👏👏 A breakthrough for kidney disease treatment: 11beta-dichloro reduces cysts in mice 🐭🐭 Researchers have discovered that a compound called 11beta-dichloro, originally developed as a cancer drug 💊, can shrink kidney cysts in mice 🐭 with a genetic condition that causes kidney failure in humans 😢. The drug works by inducing oxidative stress in the cyst cells, making them more vulnerable to cell death 💥. This could offer a new therapeutic option 💡 for patients with autosomal dominant polycystic kidney disease (ADPKD), a disease that affects more than 12 million people worldwide 🌎. Some of the merits of this drug are: - It targets the root cause of cyst formation, not just the symptoms 🎯. - It has fewer side effects than the current FDA-approved drug, tolvaptan 😌. - It could potentially prevent or delay the need for dialysis or kidney transplant 🙏. #kidneydisease #kidneyhealth #11betadichloro #ADPKD #research #breakthrough #kidneydonor #kidneyfailureawareness #kidneywarrior #kidneycancer #kidneyresearch #linkedin #dailypost